Viatris 경영진
경영진 기준 점검 3/4
Viatris CEO는 Scott Smith, Apr2023 에 임명되었습니다 의 임기는 3.08 년입니다. 총 연간 보상은 $15.27M, 9.5% 급여 및 90.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $22.05M 가치에 해당하는 회사 주식의 0.11% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.1 년과 4.5 년입니다.
핵심 정보
Scott Smith
최고경영자
US$15.3m
총 보수
| CEO 급여 비율 | 9.48% |
| CEO 재임 기간 | 3.1yrs |
| CEO 지분 보유율 | 0.1% |
| 경영진 평균 재임 기간 | 2.1yrs |
| 이사회 평균 재임 기간 | 4.5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 18
VTRS: FY26 Guidance And March Investor Event Will Shape Re Rating Potential
Analysts have raised their Viatris price target by $1.78 to $17.50, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research updates on Viatris point to a more constructive stance on the stock, with some firms lifting their valuation targets as they revisit earnings, cost savings and long term guidance assumptions.Seeking Alpha • May 11
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Summary Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now. Read the full article on Seeking Alpha
내러티브 업데이트 • May 03
VTRS: Cost Progress And FY26 Outlook Will Support Future Upside Potential
Narrative Update: Viatris The updated analyst price target for Viatris moves to $20 from $18. Analysts link the change to cost savings progress, FY26 guidance above prior consensus, and expectations for revenue growth and earnings efficiency.내러티브 업데이트 • Apr 19
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.내러티브 업데이트 • Apr 04
VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.내러티브 업데이트 • Mar 21
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.
내러티브 업데이트 • Mar 07
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.내러티브 업데이트 • Feb 20
VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.내러티브 업데이트 • Feb 06
VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.내러티브 업데이트 • Jan 23
VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.내러티브 업데이트 • Jan 09
VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.내러티브 업데이트 • Dec 25
VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.내러티브 업데이트 • Dec 11
VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.내러티브 업데이트 • Nov 27
VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.내러티브 업데이트 • Nov 13
VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.내러티브 업데이트 • Oct 30
VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.내러티브 업데이트 • Oct 15
Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.내러티브 업데이트 • Aug 27
Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
새로운 내러티브 • Apr 22
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Seeking Alpha • Feb 27
Viatris: One Swallow Doesn't Make A Summer
Summary Viatris Inc. missed estimates on sales and earnings per share. The company's 2025 guidance reveals significant challenges, including a $385 million EBITDA hit from issues at the Indore plant. We would stay out of VTRS stock. Read the full article on Seeking AlphaSeeking Alpha • Jan 24
Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Summary Viatris, formed from Mylan and Pfizer's Established Brands, has faced stock price volatility since its inception in 2020. I rated Viatris a "Buy" last October, based on management's completion of "Phase 1" of its business transformation, and initiation of "Phase 2" of their strategic plan — returning to growth. Viatris markets a mix of generic and established brand drugs, with the latter's revenues declining due to patent expiries and market competition. In a sense, the "buy"/"sell" equation is simple: grow the business in 2025, and the stock price will rise. If the top-line shrinks, investors may lose faith. Read the full article on Seeking AlphaSeeking Alpha • Jan 06
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Summary We have rated Viatris in the "neutral/hold" category since 2021. Over this time, the stock has lagged Treasury bills, despite sporting a high double digit "free cash flow yield". We tell you why that has not worked till now and why we are getting ready to trade this. Read the full article on Seeking AlphaSeeking Alpha • Nov 08
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Summary Investors cheered Viatris' Q3 2024 earnings release Thursday, bidding the stock up +13.5%. Generic pharmaceuticals have performed well and Viatris is a top idea in the space that should flourish with greater than average product launches due to the Inflation Reduction Act. Recent earnings show revenue stabilization, driven by successful new product launches, with fewer divestitures moving forward. With a stronger balance sheet and increased capital for business development, Viatris is well-positioned for share-price appreciation and dividend growth. Viatris remains a strong buy due to new product launches, a bargain valuation at 5x forward earnings, and significant debt reduction to 3x EBITDA by year's end. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$296m |
| Dec 31 2025 | US$15m | US$1m | -US$4b |
| Sep 30 2025 | n/a | n/a | -US$4b |
| Jun 30 2025 | n/a | n/a | -US$3b |
| Mar 31 2025 | n/a | n/a | -US$4b |
| Dec 31 2024 | US$15m | US$1m | -US$634m |
| Sep 30 2024 | n/a | n/a | -US$883m |
| Jun 30 2024 | n/a | n/a | -US$646m |
| Mar 31 2024 | n/a | n/a | -US$56m |
| Dec 31 2023 | US$16m | US$1m | US$55m |
보상 대 시장: Scott의 총 보수(USD15.27M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.80M) 수준입니다.
보상과 수익: Scott의 보상은 회사가 적자임에도 증가했습니다.
CEO
Scott Smith (63 yo)
3.1yrs
재임 기간
US$15,273,331
보수
Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 3.1yrs | US$15.27m | 0.11% $ 22.1m | |
| Chief Administrative & Transformation Officer | less than a year | US$4.30m | 0.019% $ 3.6m | |
| Executive Officer | no data | US$5.59m | 0.0061% $ 1.2m | |
| Chief Commercial Officer | 2.1yrs | US$5.93m | 0.0092% $ 1.8m | |
| Interim CFO | 11yrs | US$5.52m | 0.031% $ 6.1m | |
| Chief Information Officer | 2.2yrs | 데이터 없음 | 데이터 없음 | |
| Head of Investor Relations & Capital Markets | no data | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer | less than a year | 데이터 없음 | 0% $ 0 | |
| Chief People & Corporate Affairs Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief R&D Officer | 2.4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Supply Officer | 2.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Strategy Officer | 1.1yrs | 데이터 없음 | 데이터 없음 |
2.1yrs
평균 재임 기간
51yo
평균 나이
경험이 풍부한 관리: VTRS의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Director | 3.4yrs | US$15.27m | 0.11% $ 22.1m | |
| Independent Non-Executive Director | 6.3yrs | US$475.01k | 0.0088% $ 1.7m | |
| Independent Director | 5.5yrs | US$395.01k | 0.0096% $ 1.9m | |
| Independent Director | 3.4yrs | US$395.01k | 0.0054% $ 1.0m | |
| Independent Director | 5.5yrs | US$445.01k | 0.014% $ 2.7m | |
| Independent Director | 1yr | US$374.93k | 0.0022% $ 432.8k | |
| Independent Non-Executive Chairman | 13.3yrs | US$720.01k | 0.019% $ 3.7m | |
| Independent Vice Chairman & Lead Independent Director | 16.7yrs | US$525.01k | 0.014% $ 2.7m | |
| Independent Director | 1.9yrs | US$375.01k | 0.0040% $ 772.8k | |
| Independent Director | 1yr | US$324.93k | 0.0022% $ 432.8k | |
| Independent Director | 6.3yrs | US$445.01k | 0.010% $ 1.9m | |
| Independent Director | 3yrs | US$400.01k | 0.0054% $ 1.1m |
4.5yrs
평균 재임 기간
63.5yo
평균 나이
경험이 풍부한 이사회: VTRS의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 19:12 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Viatris Inc.는 31명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |